| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Ellis Andrea serves as a Director at BBIO. Across recent SEC filings that breaks down to 1 buy and 5 sells. Those positions are worth an estimated $1.9M at current prices.
Historically, Ellis Andrea's trades have earned a below-average insider score of 35/100 across 4 rated trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -48.8%.
The biggest single holding is BBIO (~$1.9M) as Director. The recent filings there lean toward selling, a net 127,255 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 17,167 | $84.00 | $1,442,028.00 | -43.2% | -26.3% | - | |
| Mar 4, 2026 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 64,921 | $64.87 | $4,211,301.92 | -77.7% | -4.0% | - | |
| Aug 5, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 17,167 | $49.00 | $841,183.00 | -48.0% | +26.0% | +66.6% | |
| Apr 14, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 10,000 | $35.00 | $350,000.00 | -45.5% | +36.8% | +114.0% | |
| Apr 1, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 30,000 | $34.05 | $1,021,500.00 | -71.4% | +30.8% | +125.5% | |
| Mar 15, 2022 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 12,000 | $8.39 | $100,680.00 | New | -30.1% | +67.5% |